Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 study to evaluate the safety and tolerability of combination therapy with
Albuvirtide (ABT) and 3BNC117 in virologically suppressed subjects with HIV-1 infection and
explore the potential of viral suppression and viral reservoir clearance after analytical
treatment interruption (ATI).